Reports optimization of CAR-iNKT designs and complementary iNKT-specific engagers to boost cell therapy efficacy against multiple myeloma.
Key Takeaways
- BCMA CAR-iNKT cells with CD28z endodomains showed the strongest anti-myeloma activity among five tested endodomains
- CD28z CAR-iNKT cells outperformed matched CAR-T cells in anti-myeloma potency
- Combining FCRL5 CAR-iNKT with a BCMA iNKT-specific engager reduced immune escape of FCRL5-negative myeloma cells